For quantitative determination of human urokinase-type plasminogen activator (uPA) and human plasminogen activator inhibitor type 1 (PAI-1) in tumor tissue extracts.
uPA and PAI-1 are important biomarkers which play a significant role in cell proliferation, invasion and metastasis of various cancers. The measurement of both uPA and PAI-1 levels is a clinically validated diagnostic tool and has achieved the highest level of evidence (LOE-1) for predicting risk of relapse and response to adjuvant therapy in breast cancer patients.
The FEMTELLE uPA/PAI-1 ELISA Test allows you to assess the likelihood of breast cancer recurrence in women with newly diagnosed, node-negative breast cancer. The test has been validated in multiple independent long-term clinical studies (>12 Jahre) with more than 8000 patients.
- FEMTELLE quantitatively determines the uPA (Urokinase-Typ Plasminogen Activator) und PAI-1 (Plasminogen Activator Inhibitor-1) levels in tumor tissue extracts. FEMTELLE allows to identify patients with high (uPA and/or PAI-1 high) and low (uPA and PAI-1 low) risk of recurrence.
- uPA und PAI-1 are the only new prognostic factors which are recommended at the highest level of evidence (LOE-1) for therapy decision in node-negative breast cancer by the German Guidelines for Diagnosis and Treatment of breast cancer.
- The test system is suitable for routine testing and clinical use. Its high reproducibility has been demonstrated in the prospective evaluation of an International Quality Assurance program.
For further information about the test please visit our Femtelle web site.
|PRODUCT NAME||REF||# of tests|
|FEMTELLE™ uPA/PAI-1 ELISA||899||96|